Profile of inotuzumab ozogamicin and its potential in the treatment of acute lymphoblastic leukemia

Monoclonal antibodies are likely to make a considerable contribution in the treatment of acute lymphoblastic leukemia (ALL). High expression of CD22 antigen is found on the surface of leukemia cells in ALL. Inotuzumab ozogamicin, a CD22 monoclonal antibody conjugated to calicheamicin, which has shown efficacy in patients with lymphomas, has also shown encouraging activity in relapsed or refractory ALL with a high morphologic and molecular response rate. This article summarizes the current approaches to treating ALL with inotuzumab ozogamicin, based on available data from the literature.

[1]  H. Kantarjian,et al.  Initial experience with CMC‐544 (inotuzumab ozogamicin) in pediatric patients with relapsed B‐cell acute lymphoblastic leukemia , 2014, Pediatric blood & cancer.

[2]  H. Kantarjian,et al.  Results of inotuzumab ozogamicin, a CD22 monoclonal antibody, in refractory and relapsed acute lymphocytic leukemia , 2013, Cancer.

[3]  H. Kantarjian,et al.  Feasibility of allografting in patients with advanced acute lymphoblastic leukemia after salvage therapy with inotuzumab ozogamicin. , 2013, Clinical lymphoma, myeloma & leukemia.

[4]  W. Stock,et al.  Weekly Inotuzumab Ozogamicin (InO) In Adult Patients With Relapsed Or Refractory CD22-Positive Acute Lymphoblastic Leukemia (ALL) , 2012 .

[5]  L. Ahlberg,et al.  High curability via intensive reinduction chemotherapy and stem cell transplantation in young adults with relapsed acute lymphoblastic leukemia in Sweden 2003–2007 , 2012, Haematologica.

[6]  H. Kantarjian,et al.  Inotuzumab ozogamicin, an anti-CD22-calecheamicin conjugate, for refractory and relapsed acute lymphocytic leukaemia: a phase 2 study. , 2012, The Lancet Oncology.

[7]  M. L. Boer,et al.  The novel calicheamicin-conjugated CD22 antibody inotuzumab ozogamicin (CMC-544) effectively kills primary pediatric acute lymphoblastic leukemia cells , 2012, Leukemia.

[8]  D. Hoelzer.  Novel antibody-based therapies for acute lymphoblastic leukemia. , 2011, Hematology. American Society of Hematology. Education Program.

[9]  R. Willemze,et al.  Intensified chemotherapy inspired by a pediatric regimen combined with allogeneic transplantation in adult patients with acute lymphoblastic leukemia up to the age of 40 , 2011, Leukemia.

[10]  A. Ricart.  Antibody-Drug Conjugates of Calicheamicin Derivative: Gemtuzumab Ozogamicin and Inotuzumab Ozogamicin , 2011, Clinical Cancer Research.

[11]  R. Foà,et al.  Flow cytometric study of potential target antigens (CD19, CD20, CD22, CD33) for antibody-based immunotherapy in acute lymphoblastic leukemia: analysis of 552 cases , 2011, Leukemia & lymphoma.

[12]  Bin-Bing S. Zhou,et al.  Preclinical anti-tumor activity of antibody-targeted chemotherapy with CMC-544 (inotuzumab ozogamicin), a CD22-specific immunoconjugate of calicheamicin, compared with non-targeted combination chemotherapy with CVP or CHOP , 2011, Cancer Chemotherapy and Pharmacology.

[13]  N. Dang,et al.  Inotuzumab ozogamicin as novel therapy in lymphomas , 2010, Expert opinion on biological therapy.

[14]  M. Tormo,et al.  Outcome after relapse of acute lymphoblastic leukemia in adult patients included in four consecutive risk-adapted trials by the PETHEMA Study Group , 2010, Haematologica.

[15]  T. Naoe,et al.  CMC‐544 (inotuzumab ozogamicin) shows less effect on multidrug resistant cells: analyses in cell lines and cells from patients with B‐cell chronic lymphocytic leukaemia and lymphoma , 2009, British journal of haematology.

[16]  T. Naoe,et al.  CMC-544 (inotuzumab ozogamicin), an anti-CD22 immuno-conjugate of calicheamicin, alters the levels of target molecules of malignant B-cells , 2009, Leukemia.

[17]  H. Dombret,et al.  Pediatric-inspired therapy in adults with Philadelphia chromosome-negative acute lymphoblastic leukemia: the GRAALL-2003 study. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[18]  H. Kantarjian,et al.  Outcome of adults with acute lymphocytic leukemia after second salvage therapy , 2008, Cancer.

[19]  C. Tripodo,et al.  In vivo targeting of human neutralizing antibodies against CD55 and CD59 to lymphoma cells increases the antitumor activity of rituximab. , 2007, Cancer research.

[20]  H. Dombret,et al.  Outcome of treatment after first relapse in adults with acute lymphoblastic leukemia initially treated by the LALA-94 trial , 2007, Leukemia.

[21]  N. Damle,et al.  Therapeutic potential of CD22-specific antibody-targeted chemotherapy using inotuzumab ozogamicin (CMC-544) for the treatment of acute lymphoblastic leukemia , 2007, Leukemia.

[22]  J. Leonard,et al.  Preclinical and clinical evaluation of epratuzumab (anti-CD22 IgG) in B-cell malignancies , 2007, Oncogene.

[23]  Rajesh Chopra,et al.  Outcome of 609 adults after relapse of acute lymphoblastic leukemia (ALL); an MRC UKALL12/ECOG 2993 study. , 2007, Blood.

[24]  J. Sancho,et al.  Results of the PETHEMA ALL‐96 trial in elderly patients with Philadelphia chromosome‐negative acute lymphoblastic leukemia , 2006, European journal of haematology.

[25]  U. Dirksen,et al.  Identification of Candidate Target Antigens for Antibody-Based Immunotherapy in Childhood B-Cell Precursor ALL , 2006, Klinische Padiatrie.

[26]  N. Damle,et al.  Antitumor Efficacy of a Combination of CMC-544 (Inotuzumab Ozogamicin), a CD22-Targeted Cytotoxic Immunoconjugate of Calicheamicin, and Rituximab against Non-Hodgkin's B-Cell Lymphoma , 2006, Clinical Cancer Research.

[27]  K. Haas,et al.  CD22: a multifunctional receptor that regulates B lymphocyte survival and signal transduction. , 2005, Advances in immunology.

[28]  N. Damle,et al.  Potent and Specific Antitumor Efficacy of CMC-544, a CD22-Targeted Immunoconjugate of Calicheamicin, against Systemically Disseminated B-Cell Lymphoma , 2004, Clinical Cancer Research.

[29]  N. Damle.  Tumour-targeted chemotherapy with immunoconjugates of calicheamicin , 2004, Expert opinion on biological therapy.

[30]  Boris Gorovits,et al.  Antibody-targeted chemotherapy with CMC-544: a CD22-targeted immunoconjugate of calicheamicin for the treatment of B-lymphoid malignancies. , 2004, Blood.

[31]  P. Frost,et al.  Antibody-targeted chemotherapy with immunoconjugates of calicheamicin. , 2003, Current opinion in pharmacology.

[32]  D. Reinhardt,et al.  Gemtuzumab ozogamicin in pediatric CD33-positive acute lymphoblastic leukemia: first clinical experiences and relation with cellular sensitivity to single agent calicheamicin , 2003, Leukemia.

[33]  J. Magaud,et al.  Acute lymphoblastic leukemia in the elderly: The Edouard Herriot hospital experience , 2001, American journal of hematology.

[34]  J. Thorson,et al.  Understanding and exploiting nature's chemical arsenal: the past, present and future of calicheamicin research. , 2000, Current pharmaceutical design.

[35]  Terry L. Smith,et al.  Primary refractory and relapsed adult acute lymphoblastic leukemia , 1999, Cancer.

[36]  M. Walker,et al.  Receptor-mediated and enzyme-dependent targeting of cytotoxic anticancer drugs. , 1999, Pharmacology & therapeutics.

[37]  M. Inaoki,et al.  CD22 negatively and positively regulates signal transduction through the B lymphocyte antigen receptor. , 1998, Seminars in immunology.

[38]  R. Bouabdallah,et al.  Age-adapted induction treatment of acute lymphoblastic leukemia in the elderly and assessment of maintenance with interferon combined with chemotherapy. A multicentric prospective study in forty patients , 1997, Leukemia.

[39]  T. Barbui,et al.  Age-adapted moderate-dose induction and flexible outpatient postremission therapy for elderly patients with acute lymphoblastic leukemia. , 1996, Leukemia & lymphoma.

[40]  O. Press,et al.  Constitutive endocytosis and degradation of CD22 by human B cells. , 1995, Journal of immunology.

[41]  E. Estey,et al.  Acute lymphocytic leukaemia in the elderly: characteristics and outsome with the vincristine‐adriamycin‐dexamethasone (VAD) regimen , 1994, British journal of haematology.

[42]  S. Walker,et al.  Cleavage behavior of calicheamicin gamma 1 and calicheamicin T. , 1992, Proceedings of the National Academy of Sciences of the United States of America.

[43]  G. Ellestad,et al.  Calicheamicin gamma 1I: an antitumor antibiotic that cleaves double-stranded DNA site specifically. , 1988, Science.